Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
2.590
-0.220 (-7.83%)
Mar 31, 2025, 2:17 PM EDT - Market open
Company Description
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine.
Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation.
The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors.
Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Tivic Health Systems, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Nov 11, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Jennifer Ernst |
Contact Details
Address: 25821 Industrial Boulevard, Suite 100 Hayward, California 94545 United States | |
| Phone | 888 276 6888 |
| Website | tivichealth.com |
Stock Details
| Ticker Symbol | TIVC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001787740 |
| CUSIP Number | 888705100 |
| ISIN Number | US8887052095 |
| Employer ID | 81-4016391 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Jennifer Ernst | Co-Founder, Chief Executive Officer and Director |
| Dr. Blake Gurfein Ph.D. | Chief Scientific Officer |
| Lisa G. Wolf | Interim Chief Financial Officer |
| Michael Kevin Handley | President of Tivic Biopharma and Chief Operating Officer of Tivic Health |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2025 | 10-K | Annual Report |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 5, 2025 | 8-K | Current Report |
| Jan 3, 2025 | DEF 14A | Other definitive proxy statements |
| Jan 3, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |